847494-64-8

Basic information

• Product Name: N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-triMethyl-4,6-Methano-1,3,2-benzodioxaborol-2-yl]-3-Methylbutyl]aMino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxaMide
• Synonyms: N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-triMethyl-4,6-Methano-1,3,2-benzodioxaborol-2-yl]-3-Methylbutyl]aMino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxaMide;MQRLCCDKPUEHCQ-ABRLXTPQSA-N
• CAS NO: 847494-64-8
• Molecular Formula: C₃₁H₄₂BN₃O₅
• Molecular Weight: 547.49328
• Product Categories: Aromatics, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 847494-64-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Solubility: Chloroform, DCM, Methanol
• CAS DataBase Reference: N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-triMethyl-4,6-Methano-1,3,2-benzodioxaborol-2-yl]-3-Methylbutyl]aMino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-triMethyl-4,6-Methano-1,3,2-benzodioxaborol-2-yl]-3-Methylbutyl]aMino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxaMide(847494-64-8)
• EPA Substance Registry System: N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-triMethyl-4,6-Methano-1,3,2-benzodioxaborol-2-yl]-3-Methylbutyl]aMino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxaMide(847494-64-8)

Safety Data

• Hazardous Substances Data: 847494-64-8(Hazardous Substances Data)

Usage

Uses

N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxamide is an intermediate in the synthesis of Delanzomib (D230710), an orally active proteasome inhibitor.

Upstream product

• 514820-48-5 1,1,1-trimethyl-N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-N-(trimethylsilyl)silanamine 
• 1247729-31-2 C₁₆H₁₆N₂O₄ 
• 779357-85-6 (1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutylamine hydrochloride 
• 1247729-30-1 6-phenyl-pyridine-2-carbonyl chloride 
• 39774-28-2 6-phenyl-pyridine-2-carboxylic acid 
• 779357-85-6 (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxabor-ol-2-yl]butan-1-amine hydrochloride 
• 847494-19-3 (2S,3R)-2-amino-3-hydroxybutanamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-, hydrochloride salt 

Downstream Products

• 847499-27-8 Delanzomib 

Relevant articles and documents

Proteasome inhibitor delanzomib for use in the treatment of lupus

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

The ubiquitin-proteasome pathway plays a central role in regulation of the production and destruction of cellular proteins. These pathways mediate proliferation and cell survival, particularly in malignant cells. The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy. Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclinical development, [(1R)-1-[[2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl] amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed.